Abiomed (ABMD) Reports Preliminary Revenue of $114.7M, Vs Cons of $113.14M; Sees FY17 Revs of $435-$445M Vs Cons of $444.7M

Abiomed, Inc. (NASDAQ: ABMD) reported preliminary, unaudited, third quarter fiscal 2017 revenue of approximately $114.7 million, an increase of 34% compared to revenue of $85.8 million for the same period of fiscal 2016. *** The consensus is $113.14 billion.

• Preliminary unaudited U.S. revenue from Impella® products grew 34% to approximately $100.3 million from $75.0 million in the prior fiscal year.
• For the third quarter of fiscal 2017, U.S. patient usage grew 32% in comparison with same period of fiscal 2016. Protected PCI patient usage grew 34% and emergent patient usage grew 36%, year-over-year.

The preliminary unaudited revenue results described in this press release are estimates only and are subject to revision until the Company reports its full financial results for the third quarter of fiscal 2017 on January 26, 2017.

These preliminary results are being provided in advance of the Company's presentation at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco. Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed, will present at 9:30 a.m. PT/12:30 p.m. ET on Wednesday, January 11, 2017.

A live webcast of the Company's presentation at the conference will be available via http://jpmorgan.metameetings.com/confbook/healthcare17/directlink?p=22722 as well as on the investor section of the Company's website at www.abiomed.com. A replay of the webcast will be available for 90 days after the presentation.

FISCAL YEAR 2017 OUTLOOKThe Company is maintaining its fiscal year 2017 revenue guidance of $435 million to $445 million, an increase in revenue of 32% to 35% from the prior year. The Company is also maintaining its fiscal year guidance for GAAP operating margin to be in the range of 18% to 20%. *** The consensus is $444.7 million.

EARNINGS CONFERENCE CALL DETAILSThe Company will release full quarterly results for the third quarter of fiscal 2017 via conference call on Thursday, January 26, 2017.

The conference call releasing full quarterly results will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Michael Tomsicek, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. EST January 26, 2017 through 11 a.m. EST on January 29, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 44227123.

You May Also Be Interested In

• Hasbro (HAS) brand strength sees earnings top expectations
• Massimo Group (MAMO) Expands Partnership with Global Omnichannel Retailer for Youth Series Vehicles
• Blue Foundry Bancorp (BLFY) Tops Q1 EPS by 9c